DSMFF Stock Chart & Stats
$110.27
$0.00(0.00%)
At close: 4:00 PM EDT
$110.27
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$61.05 - $122.91
Previous CloseN/A
Volume32.00
Average Volume (3M)91.00
Market Cap
$28.03B
Enterprise Value$25.37B
Total Cash (Recent Filing)$2.31B
Total Debt (Recent Filing)$6.76B
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Feb 18, 2027EPS Estimate
1.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.82
Shares Outstanding253,626,950
10 Day Avg. Volume0
30 Day Avg. Volume91
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit6.35
Enterprise Value/Ebitda12.27
Forecast
1Y Price Target
$102.73Price Target Upside-6.84% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)4.13
Revenue Forecast (FY)$10.40B
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Gross-margin ImprovementThe strong revenue rebound indicates renewed demand across the company’s specialty ingredient activities, while higher gross margin suggests improved pricing, mix, or cost control. Together, these trends strengthen the foundation for rebuilding profitability over the next several quarters.
Positive Cash GenerationPositive operating and free cash flow provides internal funding for investment, debt service, and customer-focused innovation despite reported losses. Continued cash conversion would improve financial resilience and give management greater flexibility while earnings recovery remains incomplete.
Manageable Leverage And Substantial Equity CushionModerate leverage relative to the company’s equity base provides a meaningful balance-sheet cushion and reduces immediate financial pressure. This supports continued operation and investment across its specialty chemicals businesses while management works to restore sustainable shareholder returns.
Bears Say
Persistent Net LossesSustained negative net margins show that the recent revenue recovery has not yet translated into bottom-line earnings. Continued losses can constrain reinvestment, weaken shareholder returns, and make the durability of the company’s financial improvement less certain.
Volatile And Weakening Operating ProfitabilityThe decline in operating margin alongside a shift from prior profits to recent losses points to an unstable earnings profile. This volatility makes it harder to assess normalized profitability and indicates that stronger sales have not yet produced dependable operating leverage.
Rising Leverage And Limited Debt CoverageAlthough leverage remains moderate, its recent increase and only partial operating-cash-flow coverage of debt reduce financial flexibility. If profitability does not recover, a larger share of internally generated cash may remain committed to obligations rather than growth or shareholder returns.
DSM-Firmenich AG News
DSMFF FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
DSM-Firmenich AG lowest stock price was $61.05 and its highest was $122.91 in the past 12 months.
What is DSM-Firmenich AG’s market cap?
DSM-Firmenich AG’s market cap is $28.03B.
When is DSM-Firmenich AG’s upcoming earnings report date?
DSM-Firmenich AG’s upcoming earnings report date is Feb 18, 2027 which is in 125 days.
How were DSM-Firmenich AG’s earnings last quarter?
DSM-Firmenich AG released its earnings results on Jul 30, 2026. The company reported $1.015 earnings per share for the quarter, missing the consensus estimate of $1.03 by -$0.015.
Is DSM-Firmenich AG overvalued?
According to Wall Street analysts DSM-Firmenich AG’s price is currently Overvalued.
Does DSM-Firmenich AG pay dividends?
DSM-Firmenich AG does not currently pay dividends.
What is DSM-Firmenich AG’s EPS estimate?
DSM-Firmenich AG’s EPS estimate is 1.71.
How many shares outstanding does DSM-Firmenich AG have?
DSM-Firmenich AG has 253,626,950 shares outstanding.
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
DSM-Firmenich AG reported an EPS of $1.015 in its last earnings report, missing expectations of $1.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DSM-Firmenich AG?
Currently, no hedge funds are holding shares in DSMFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
DSMFF Stock 12 Month Forecast
Average Price Target
$102.73
▼(-6.84% Downside)
Technical Analysis
Ownership Overview
―
Insiders
11.61% Mutual Funds
0.17% Other Institutional Investors
76.11% Public Companies and
Individual Investors